thumbnail image
    • HOME
    • ABOUT
    • LEADERSHIP
    • NEWS
    • CONTACT
    • …  
      • HOME
      • ABOUT
      • LEADERSHIP
      • NEWS
      • CONTACT
    broken image
      • HOME
      • ABOUT
      • LEADERSHIP
      • NEWS
      • CONTACT
      • …  
        • HOME
        • ABOUT
        • LEADERSHIP
        • NEWS
        • CONTACT
      broken image
      • INTERSTICE

        THERAPEUTICS, LLC

      • ABOUT

        broken image

        Interstice Therapeutics, LLC

        Mission

        Interstice Therapeutics, LLC is a biotech company focused on rapid development and approval of novel 505b(2) drugs to address anticipated and/or real world branded New Drug Application (NDA) treatment adoption gaps.

      • LEADERSHIP

        broken image

        Andrew H. Isaacs

        President & CEO

        Thirty years proven record of achievements in leading Global Operations, Strategic Planning, New Product Development, Marketing, Business Development, Change Management, Technology Assessments and Implementation, Medical Education, Brand Launches, Sales Teams, and Technology Alliances, from concept through launch of products and added value services.


        BioMedical Engineering undergraduate degree from Boston University, dual MBA/MS graduate degrees from Kean University, and Superior Product Development certificate from Harvard Business School.

      • NEWS

        February 2025

        Interstice Therapeutics, LLC awaiting USPTO response and/or issuance of an allowance of claims.

        January 2025

        Interstice Therapeutics, LLC develops initial Investor Presentation in anticipation of USPTO issuance of patent.

        October 2024

        Interstice Therapeutics, LLC conducts second live teleconference call with USPTO Examiner and files supplementary support documentation.

        August 2024

        Interstice Therapeutics, LLC engages therapeutic Subject Matter Expert to support pharmacology claims.

        2019-2023

        Interstice Therapeutics, LLC continues application process with the United States Patent Office.

        October 15, 2018

        Interstice Therapeutics, LLC files a Patent Application with the United States Patent Office for their first novel combination drug.

        October 18, 2017

        Interstice Therapeutics, LLC files first combination drug Provisional Patent with the United States Patent Office.

      • CONTACT

        broken image

        Email

        Andrew.Isaacs@IntersticeTherapeutics.com
        broken image

        Phone

        908-229-2199

      © 2024

        Cookie Use
        We use cookies to ensure a smooth browsing experience. By continuing we assume you accept the use of cookies.
        Learn More